Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of respiratory disease drugs will reach $24 billion in 2007. Diseases included in this market are chronic obstructive pulmonary disease (COPD), allergic rhinitis, and asthma. According to the new DR Pipeline Report entitled Pipeline Analysis of Key Players in the Respiratory Disease Market, GlaxoSmithKline dominated the market in 2002 with a 23% share.

"GlaxoSmithKline offers the broadest range of respiratory products, led by the recently launched asthma treatment Advair. Going forward, however, GlaxoSmithKline will have to focus on maximizing the uptake of Advair and its use in the treatment of COPD, since it lacks any major late-stage respiratory products in development, excluding line extensions," said Tracy DeGregorio, director of DR Pipeline Reports at Decision Resources. "The recent recommendation that the FDA should not approve the use of cilomilast for the treatment of COPD without additional studies, the cannibalization of sales of Flovent and Seretide by Advair, and the maturity of its respiratory portfolio leaves the company with no other near-term prospects of enhancing its substantial revenues from a key therapeutic franchise."

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. The 2003 Pipeline series reveals which compounds are most clinically effective and commercially viable within five therapeutic markets: major metabolic diseases, psychiatric disorders, gastrointestinal diseases, respiratory diseases, and viral infections.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Influenza Drug Market Sales To Reach $2.5 Billion In 2012

View Now